Kennen MacKay – RBC Capital

RBC Capital

An RBC Capital analyst with 8 tracked ratings across 8 distinct tickers has a 30% success rate on the captured sample, covering two sources.

Aggregated from multiple market-data sources

Total ratings

Tickers covered

Sources

Aggregated

Latest rating

2 years ago

2024-04-17 00:00:00+00

Track record

Aggregated

30% success rate

Bullish: 0
Hold: 0
Bearish: 0

Aggregated

Not available

Bullish: 1
Hold: 0
Bearish: 0

Recent ratings

Ticker	Date	Rating	Price target	Source
NUVBNUVATION BIO INC - ORDINARY SHARES - CLASS A	2024-04-17	unknown	$5.00	Aggregated
AGIOAGIOS PHARMACEUTICALS INC	2023-06-27	unknown	$42.00	Aggregated
AMGNAMGEN INC.	2021-12-21	unknown	$218.00	Aggregated
ADCTADC THERAPEUTICS SA	2021-11-03	unknown	$34.00	Aggregated
EXELEXELIXIS INC	2021-11-03	unknown	$31.00	Aggregated
LIFEETHOS TECHNOLOGIES INC. CLASS A COMMON STOCK	2021-10-12	unknown	$22.00	Aggregated
PRTAPROTHENA CORPORATION PLC	2021-09-30	unknown	$82.00	Aggregated
PBYI	2021-08-06	unknown	$6.00	Aggregated
ABEO	2020-03-18	buy	$11.00	Aggregated

Tickers covered(9)

Ticker	Ratings	Last rating	Sources
NUVBNUVATION BIO INC - ORDINARY SHARES - CLASS A	1	2024-04-17	Aggregated
AGIOAGIOS PHARMACEUTICALS INC	1	2023-06-27	Aggregated
AMGNAMGEN INC.	1	2021-12-21	Aggregated
ADCTADC THERAPEUTICS SA	1	2021-11-03	Aggregated
EXELEXELIXIS INC	1	2021-11-03	Aggregated
LIFEETHOS TECHNOLOGIES INC. CLASS A COMMON STOCK	1	2021-10-12	Aggregated
PRTAPROTHENA CORPORATION PLC	1	2021-09-30	Aggregated
PBYI	1	2021-08-06	Aggregated
ABEO	1	2020-03-18	Aggregated

Methodology differs by source. Track records are aggregated from multiple sources; scoring methodology and scales differ by source and values are not directly comparable. Coverage is sourced from publicly-aggregated analyst activity. Past performance does not guarantee future results. Not investment advice.